Related Experiment Video
Updated: Jun 9, 2025
12:54
Transient Expression of Proteins by Hydrodynamic Gene Delivery in Mice
Published on: May 5, 2014
28.5K
Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease
1Laboratory of Molecular Parasitology, Institut de Biologie et de Médecine Moléculaires (IBMM), Université Libre de Bruxelles, 6041 Gosselies, Belgium.
Cells
|October 25, 2024
Summary
Apolipoprotein-L1 (APOL1) variants provide resistance to African trypanosomes but can cause kidney podocyte damage. This toxicity is linked to plasma membrane disturbance and cholesterol interaction, not pore formation.
Area of Science:
- Immunology
- Molecular Biology
- Pathology
Background:
- Apolipoprotein-L1 (APOL1) confers resistance to African trypanosomes.
- APOL1 variants (G1, G2) linked to kidney disease arise from mutations.
- The precise mechanism of APOL1-induced podocyte toxicity is debated.
Purpose of the Study:
- To review the mechanism of APOL1-induced podocyte toxicity.
- To differentiate between pore formation and membrane interaction hypotheses.
- To discuss the evolutionary interplay between host defense and parasite adaptation.
Main Methods:
- Review of existing literature on APOL1 function and toxicity.
- Analysis of APOL1's biophysical properties under different conditions.
- Comparison of APOL1 activity in trypanosomes versus human podocytes.
Main Results:
- APOL1 toxicity in podocytes occurs under non-acidic conditions, unlike pore formation.
- APOL1 variants increase hydrophobicity and interact with cholesterol in podocyte membranes.
- A specific mutation (N264K) reduces toxicity while slightly increasing trypanosome sensitivity.
Conclusions:
- APOL1 variant toxicity in podocytes results from plasma membrane disturbance via cholesterol interaction, not pore formation.
- This mechanism highlights the complex trade-offs in host-parasite co-evolution.
- Understanding APOL1's membrane interactions is crucial for treating APOL1-associated nephropathies.
